Algorae Pharmaceuticals Ltd

1AI

Company Profile

  • Business description

    Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

  • Contact

    525 Collins Street
    Level 23, Rialto South Tower
    MelbourneVIC3000
    AUS

    T: +61 422180317

    https://www.algoraepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    48

Stocks News & Analysis

stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.
stocks

AI stocks winners, laggards and losers for 2025

AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.
stocks

12 picks for an income portfolio - Q4 2025 update

Eighteen months in and passive income growth has exceeded my target.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,085.9018.700.21%
CAC 408,362.09118.631.44%
DAX 4025,261.64134.180.53%
Dow JONES (US)49,504.07237.960.48%
FTSE 10010,124.6079.910.80%
HKSE26,442.30210.510.80%
NASDAQ23,671.35191.330.81%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,665.3530.90-0.23%
S&P 5006,966.2844.820.65%
S&P/ASX 2008,751.4017.800.20%
SSE Composite Index4,151.1430.710.75%

Market Movers